Drugs A - Z

Fentanyl Citrate Oral lozenge

It is used to treat breakthrough cancer pain that your long acting pain medicine does not control

Generic Name: fentanyl transmucosal  |  Brand Name: Actiq

Brand Names: Fentanyl Citrate, Actiq

There is an FDA Alert for this drug. Click here to view it.

    Transdermal Systems
  • Indicated only for the management of persistent, moderate to severe pain that requires continuous, around the clock opiate administration for an extended period of time and that cannot be managed by other means (e.g., NSAIAs, opiate combination preparations, immediate-release opiates).
  • Use only in opiate-tolerant patients who require a total daily opiate dosage equivalent to ≥25 mcg of transdermal fentanyl per hour. Opiate-tolerant patients are those who have been receiving ≥60 mg of oral morphine sulfate daily, ≥30 mg of oral oxycodone hydrochloride daily, ≥8 mg of oral hydromorphone hydrochloride daily, or equianalgesic dosage of another opiate for ≥1 week.
  • Contraindicated because of potential for serious or life-threatening hypoventilation in patients not already opiate tolerant; in patients requiring opiate analgesia for only a short period of time; in the management of acute pain or postoperative pain, including in outpatient surgery or day surgeries (e.g., tonsillectomies); and in the management of mild or intermittent pain (e.g., use on an as-needed [“prn”] basis).
  • Peak fentanyl concentrations occur 24–72 hours following application; serious or life-threatening hypoventilation (even in opiate-tolerant patients) may occur at any time, but particularly during initial application period and after increases in dosage. (See Respiratory Depression under Cautions.)
  • Risk of fatal overdose secondary to respiratory depression. Fatal overdose is possible with the first transdermal dose in patients being switched from other opiate preparations if the transdermal dose is overestimated. Due to long elimination half-life (17 hours), patients experiencing severe adverse effects (including overdosage) should be monitored and treated for ≥24 hours.
  • Concomitant use with any CYP3A4 inhibitor may result in increased plasma fentanyl concentrations, which could increase or prolong adverse effects, potentially resulting in fatal respiratory depression. (See Interactions.) If used concomitantly, carefully monitor patients for an extended period and adjust dosage if warranted.
  • Do not expose transdermal application site or surrounding area to direct external heat sources, since this could increase release of fentanyl from the transdermal system and potentially result in overdosage and death. Closely observe febrile patients and individuals whose core body temperature increases following strenuous exercise for manifestations of opiate toxicity; adjust dosage accordingly. (See Patients with Fever or Exposure to High Temperatures under Cautions.)
  • For transdermal use on intact skin only. Do not use transdermal system if the seal is broken or if the system is damaged, cut, or altered. Use of such systems may expose the patient or caregiver to the contents of the system and result in rapid release of fentanyl and absorption of a potentially fatal dose of the drug.
  • Safety in children <2 years of age not established. Use in children ≥2 years of age only if opiate tolerant.
  • Potential for abuse of fentanyl is similar to that of other opiates. Transdermal systems may be a particular target for abuse and diversion because of high fentanyl content. Clinicians should consider abuse potential when administering, prescribing, or dispensing fentanyl transdermal systems in situations where they are concerned about an increased risk of misuse, abuse, or diversion. Individuals at risk for opiate abuse include those with a personal or family history of substance abuse (e.g., alcohol or drug abuse or addiction) or psychiatric disorders (e.g., major depression). Assess patient for abuse or addiction potential before prescribing opiates; monitor for misuse, abuse, and addiction during therapy. Patients at risk of abuse may be treated with modified-release opiate preparations; however, intensive monitoring is needed.

    Buccal (Transmucosal) Tablets and Lozenges
  • Serious adverse events, including deaths, have occurred because of improper patient selection (e.g., use in non-opiate-tolerant patients) and/or improper dosage in patients receiving the buccal tablets. Substitution of buccal tablets for any other fentanyl preparation may result in fatal overdosage. (See Dosage: Breakthrough Malignant [Cancer] Pain under Dosage and Administration.)
  • Do not use buccal tablets and lozenges interchangeably (e.g., on a mcg-per-mcg basis); buccal tablets are more bioavailable than buccal lozenges. Dosage adjustment required. (See Table 1 in Dosage and Administration.)
  • Buccal tablets and lozenges indicated only for the management of breakthrough malignant (cancer) pain in patients who already are receiving and tolerant of around-the-clock opiate therapy for their underlying persistent cancer pain.
  • Opiate-tolerant patients are those who have been receiving around-the-clock therapy with ≥60 mg of morphine sulfate daily, ≥25 mcg of transdermal fentanyl per hour, ≥30 mg of oral oxycodone hydrochloride daily, ≥8 mg of oral hydromorphone hydrochloride daily, or an equianalgesic dosage of another opiate for ≥1 week.
  • Buccal preparations contraindicated in the management of acute pain (e.g., injuries, migraine, other headaches) or postoperative pain because serious or life-threatening hypoventilation can occur at any dose in patients not chronically taking opiates.
  • Buccal preparations contraindicated in patients not already opiate tolerant. Deaths reported in non-opiate-tolerant patients.
  • Buccal preparations intended for use only in cancer care and only by oncologists and pain specialists knowledgeable about the use of schedule II opiates in such patients.
  • Buccal tablets require special care in dosing. If breakthrough pain is not relieved after 30 minutes, the patient may take only 1 additional dose (using the same-strength tablet) and then must wait at least 4 hours before taking another dose. (See Dosage: Breakthrough Malignant [Cancer] Pain under Dosage and Administration.)
  • Instruct patients and their caregivers that the buccal tablets and lozenges contain fentanyl in an amount that can be fatal to a child. Instruct patients and their caregivers to keep the buccal tablets and lozenges out of reach of children and to discard open units properly.
  • Concomitant use of buccal preparations with potent or moderately potent CYP3A4 inhibitors may result in increased plasma fentanyl concentrations, which could potentially result in fatal respiratory depression. (See Interactions.)
  • Potential for abuse is similar to that of other opiates. Clinicians should consider abuse potential when administering, prescribing, or dispensing fentanyl buccal preparations in situations where they are concerned about an increased risk of misuse, abuse, or diversion.

REMS:

FDA approved a REMS for fentanyl to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of fentanyl and consists of the following: medication guide, elements to assure safe use, communication plan, and implementation system. See the FDA REMS page ([Web]) or the ASHP REMS Resource Center ([Web]).

What is this medicine?

FENTANYL (FEN ta nil) is a pain reliever. It is used to treat breakthrough cancer pain that your long acting pain medicine does not control. Do not use this medicine for a pain that will go away in a few days like pain from surgery, doctor or dentist visits. The medicine is used only by people who have been taking an opioid or narcotic pain medicine for at least a week.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
  • brain tumor
  • dental disease
  • diabetes mellitus
  • drug abuse or addiction
  • head injury
  • heart disease
  • if you frequently drink alcohol containing drinks
  • kidney disease or problems going to the bathroom
  • liver disease
  • lung disease, asthma, or breathing problems
  • mental problems
  • skin problems
  • use of a MAOI like Carbex, Eldepryl, Marplan, Nardil, and Parnate in the past 14 days
  • an unusual or allergic reaction to fentanyl, other opioid analgesics, other medicines, foods, dyes, or preservatives
  • pregnant or trying to get pregnant
  • breast-feeding

How should I use this medicine?

Follow the directions on the prescription label. Cut open the package using scissors, and remove the unit. Do not open the package until you are ready to use it. Place the unit in your mouth between your cheeks and gum and suck on it. Move the unit from one side of your mouth to the other every couple of minutes. Twirl the handle often. Do not bite or chew the unit. If you feel dizzy or sick to your stomach before you have finished the medicine, remove the unit from your mouth. Throw the handle away in a place that is out of the reach of children and pets. If medicine remains on the handle, place the handle under hot running tap water until the unit is gone. Then, throw the handle away out of the reach of children and pets. If you did not finish the entire unit and you cannot immediately get rid of the medicine, put the unit in the temporary storage bottle that you have received in the Welcome Kit. Push the unit into the opening on the top of the unit it falls completely into the bottle. NEVER leave unused or partly used units where children or pets can get to them. Empty the storage bottle, and run the handles under hot tap water to get rid of the medicine at least once a day.

The unit should be consumed over a 15 minute period. Do not use a second unit without checking with your doctor or health care professional. While your exact dose is being determined, you may need to use more than one unit to control your pain. Wait at least 30 minutes after starting a unit and 15 minutes after finishing a unit before using another.

Do not take your medicine more often than directed. Do not suddenly stop taking your medicine because you may develop a severe reaction. Your body becomes used to the medicine. This does NOT mean you are addicted. Addiction is a behavior related to getting and using a drug for a non-medical reason. If you have pain, you have a medical reason to take pain medicine.

A special MedGuide will be given to you by the pharmacist with each prescription and refill. Be sure to read this information carefully each time.

Talk to your pediatrician regarding the use of this medicine in children. While this drug may be prescribed for children as young as 16 years for selected conditions, precautions do apply.

Patients over 65 years old may have a stronger reaction and need a smaller dose.


Last Updated: August 22, 2012
Licensed from
The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.
 

Fentanyl transmucosal

 
Advertisement
Advertisement